S&P raises King Pharmaceuticals outlook to stable

Standard & Poor's said it revised its rating outlook on King Pharmaceuticals Inc. to stable from negative.

At the same time, S&P said it affirmed its BB corporate credit rating on the company.

The ratings on King Pharmaceuticals reflect the looming competitive challenges facing a number of the company's core products, an uncertain product pipeline and the potential need for significant debt-financed product acquisitions, the agency said.

Still, S&P noted that King has a relatively diverse product portfolio and remains very conservatively financed.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.